Summit Therapeutics’ Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

Summary
  • Summit Therapeutics specializes in developing innovative therapeutic solutions for oncology and infectious diseases.
  • Their flagship drug candidate, Ivonescimab, is in phase 3 clinical trials and shows promise in treating non-small cell lung cancer.
  • The company’s Ivonescimab, a bispecific antibody, is supported by a partnership with Akeso. Ivonescimab targets PD-1 and VEGF pathways, potentially treating NSCLC and other cancers.
  • Summit’s promising clinical trials, HARMONi and HARMONi-3, focus on advanced lung cancers and aim for FDA approval.
  • SMMT is a strong buy because of ivonescimab’s potential in oncology and the company’s proven leadership under Robert Duggan.

Summit Therapeutics Inc. (NASDAQ:SMMT) discovers, develops, and commercializes therapeutic solutions in oncology. Currently, SMMT’s flagship drug candidate is Ivonescimab, which is in phase 3 clinical trials in the US. This bispecific antibody targets the PD-1 protein receptor and boosts the immune

READ FULL ARTICLE HERE!